Diligence memo · auto-generated · as of July 3, 2026

Fresenius Medical Care North Elkhart, LLC

Fresenius Medical Care North Elkhart, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Fresenius Medical Care North Elkhart, LLC operates in Healthtech, based in WALTHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Fresenius Medical Care North Elkhart, LLC has raised $2.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.5M on 2019-10-31.

Most recent recorded round closed around 2019-10-31.

Valuation (modeled)modeled

Provath models Fresenius Medical Care North Elkhart, LLC at approximately $70M (range $2.1M–$548M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.52× the median modeled value of Seed Healthtech companies in 2019–2021 (180 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 6.7 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 42% of Healthtech peers (2138 compared).

Modeled value ranks above 69% of those peers.

Closest niche peers: Hippo Health, Inc., Primacy Health Inc., Ursa Major Natural Care, Inc., Able Health Inc., Gentem Health Inc.

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.